Flare Therapeutics is a biotechnology research startup that is revolutionizing the approach to transcription factor biology for developing small molecule medicines. With a focus on precision oncology, Flare's drug discovery to target 'switch sites' that hold the control for predictable and profound changes in DNA transcription has resulted in a rapidly advancing pipeline of drug programs. Their small molecules are designed to regain transcriptional control that is hijacked by cancer. 

With an oversubscribed Series B financing round that raised $123 million, Flare has the backing of several prominent investors, including Pfizer, Casdin Capital, ShangBay Capital, Nextech Invest, Novartis, Third Rock Ventures, Agent Capital, Eventide Asset Management, Boxer Capital, and GordonMD® Global Investments LP. Led by founder Amit Rakhit, the Flare team is a passionate and brilliant group of individuals who are determined to make a significant impact in the field of biotech research. Their first-in-class PPARG inhibitor, FX-909, is set to enter clinical trials in 2023, furthering their mission to light up the therapeutic space and develop novel transcription factor targets for oncology. Join Flare's team of talented minds and be part of the future of biotech research.